Johnson & Johnson (JNJ) — closed signal from April 15, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on July 14, 2026.
Predicted vs. what happened
JNJ price · publication thesis → realized outcomesplit-adjusted
$235.00 – $241.00Entry zone — fair-value band
$237.76Published — price the day we called it
$256.78Target — the price the thesis aimed for
$269.43Peak — highest point inside the window, not a realized return
$253.85Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 75 days.
Peak price
$269.43
peak on July 7, 2026 — not a realized returnPeak gain
+13.3%
peak, from the publication priceWindow close
$253.85
end-of-window price, context onlyDays to target
75
Window
April 15, 2026 – July 14, 2026
The thesis — published April 15, 2026
Predicted growth
+8%
over the measurement windowTarget price
$256.78
the price the thesis aimed forEntry zone
$235.00 – $241.00
the fair-value band we waited forPrice at publication
$237.76
published April 15, 2026Confidence
80%
how strongly the data lined upTimeframe
Short-term (0–3 months)
We see J&J as a steadier short-term holding because recent results showed stronger sales, management raised the full-year outlook, and the dividend was increased. Momentum is coming from cancer treatments and newer products, and shares are not as crowded as many fast-growing large caps. Upside is smaller, but downside appears better protected.
Primary drivers
- Raised outlook and a bigger dividend improve visibility
- Momentum from oncology and newer product sales
- Shares are trading from a less crowded position
- Stable cash flow offsets riskier growth names
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.